PARENTERAL AMINOSIDINE IS NOT EFFECTIVE FOR PERUVIAN MUCOCUTANEOUS LEISHMANIASIS.


Llanos-Cuentas, A; Echevarria, J; Seas, C; Chang, E; Cruz, M; Alvarez, E; Rosales, E; Campos, P; Bryceson, A; (2007) PARENTERAL AMINOSIDINE IS NOT EFFECTIVE FOR PERUVIAN MUCOCUTANEOUS LEISHMANIASIS. The American journal of tropical medicine and hygiene, 76 (6). pp. 1128-1131. ISSN 0002-9637

[img]
Preview
Text - Published Version
License: Copyright the publishers

Download (70kB) | Preview

Abstract

Few therapeutic options are available for mucocutaneous leishmaniasis (MCL). We conducted a randomized open trial to evaluate the efficacy, safety, and tolerance of parenteral aminosidine sulphate (AS) 14 mg/kg/d for 21 days compared with intravenous meglumine antimonate (MA) 20 mg/kg/d for 28 days in patients with moderate MCL in Cuzco, Peru. Cure was defined as complete healing with re-epithelialization within 1 year of follow-up. The trial was stopped after 38 patients were enrolled (17 in the MA group and 21 in the AS group) because of marked differences in response. Study groups were comparable in baseline characteristics. Cure rates were 0/21 in the AS group compared with 8/17 (47%, 95% confidence interval: 23-71%) in the MA group (P < 0.001). Side effects and laboratory abnormalities were mild in both groups. We conclude that parenteral AS given on its own is not effective for MCL in Peru.

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Clinical Research
Research Centre: Leishmaniasis Group
PubMed ID: 17556623
Web of Science ID: 247116500024
URI: http://researchonline.lshtm.ac.uk/id/eprint/9845

Statistics


Download activity - last 12 months
Downloads since deposit
4Downloads
293Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item